Key catalysts approach for Orphazyme, Gemini and Immutep.
The group discontinues its first-generation antisense Huntington’s projects on disappointing efficacy, leaving its next-gen asset with much to prove.
The company might finally become an oncology player.
The second quarter brings updates for Scholar Rock, Alnylam and Dicerna, among others.
Boehringer says its inhaled antibody could reach the patients IV antibodies cannot, but will be “very happy” if it isn’t needed.
The failure of Roche and Ionis’s late-stage candidate tominersen casts doubt on Wave’s approach, too.
The group hopes for a better result with a higher dose of its antisense projects, but it also has a back-up plan.